Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15151 - 15175 of 15369 in total
Experimental
Experimental
Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Withdrawn
Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
Investigational
Investigational
(3S)-1-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}pyrrolidine-3-thiol is a solid. This compound belongs to the benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring. This substance is known to target disintegrin and metalloproteinase domain-containing protein 17.
Experimental
Matched Description: … This substance is known to target disintegrin and metalloproteinase domain-containing protein 17. …
Experimental
Displaying drugs 15151 - 15175 of 15369 in total